These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21305727)

  • 21. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
    Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
    Ophthalmology; 2012 Dec; 119(12):2587-91. PubMed ID: 22902212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.
    Kreutzer TC; Alge CS; Wolf AH; Kook D; Burger J; Strauss R; Kunze C; Haritoglou C; Kampik A; Priglinger S
    Br J Ophthalmol; 2008 Mar; 92(3):351-5. PubMed ID: 18211925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.
    Prager F; Michels S; Kriechbaum K; Georgopoulos M; Funk M; Geitzenauer W; Polak K; Schmidt-Erfurth U
    Br J Ophthalmol; 2009 Apr; 93(4):452-6. PubMed ID: 19074916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreous bevacizumab treatment for macular edema due to central retinal vein occlusion.
    Axer-Siegel R; Dotan A; Mimouni K; Bor E; Weinberger D; Bourla DH
    Curr Eye Res; 2012 Sep; 37(9):818-22. PubMed ID: 22668313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
    Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
    Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.
    Funk M; Kriechbaum K; Prager F; Benesch T; Georgopoulos M; Zlabinger GJ; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.
    Kondo M; Kondo N; Ito Y; Kachi S; Kikuchi M; Yasuma TR; Ota I; Kensaku M; Terasaki H
    Retina; 2009 Oct; 29(9):1242-8. PubMed ID: 19672216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
    Ehlers JP; Decroos FC; Fekrat S
    Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin): preliminary results.
    Pournaras JA; Nguyen C; Vaudaux JD; Konstantinidis L; Ambresin A; Wolfensberger T
    Klin Monbl Augenheilkd; 2008 May; 225(5):397-400. PubMed ID: 18454380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
    Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
    Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
    Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
    Retina; 2007; 27(4):419-25. PubMed ID: 17420692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab.
    Abegg M; Tappeiner C; Wolf-Schnurrbusch U; Barthelmes D; Wolf S; Fleischhauer J
    BMC Ophthalmol; 2008 Sep; 8():18. PubMed ID: 18823536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
    Lim JW
    Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Ophthalmologica; 2009; 223(2):124-7. PubMed ID: 19088494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
    Tao Y; Hou J; Jiang YR; Li XX; Jonas JB
    Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.